Be-cause Health & QUAMED literature updates
Ref Hauk C, SchafermannS, Martus P, Muzafarova N, Babaley M, Waning B, et al. (2020) Quality assurance in anti-tuberculosis drug procurement by the Stop TB Partnership—Global Drug Facility: Procedures, costs, time requirements, and comparison of assay and dissolution results by manufacturers and by external analysis. PLoS ONE 15(12): e0243428.
I am happy to share a new paper from our friends at Tübingen University, which will be of great interest for many of us. In addition, I also attach an update of our informal “Fact-sheet on poor-quality medicines” (ed. see the link below this article).
Arguably, one of the most effective interventions to counter the problem of substandard and falsified medicines is to strengthen quality assurance in drug procurement. Quality-assured medicines are of particular importance in the case of anti-tuberculosis medicines since poor quality anti-TB medicines are among the drivers of the emergence of drug-resistant TB pathogens.
The Global Drug Facility (GDF) of the Stop TB Partnership, founded in 2001, is the world’s largest provider of TB products for national TB control programs. In this study, carried out in a collaboration between the group of Prof. Lutz Heide at Tübingen University, Germany, and the team of GDF in Geneva, Switzerland, procedures and results of GDF’s quality assurance/quality control (QA/QC) over the five-year period 2013-2017 were analysed retrospectively.
Overall, 13,999 batches of 51 different medicines had been procured and reviewed within this period. 1,388 of these batches had been analysed by an external quality control agent of GDF. This study summarizes the procedures, costs and time requirements of this operation. The reported data may provide a benchmark for other organizations to evaluate and improve their procedures in the assurance of medicine quality in drug procurement.
Importantly, assay and dissolution results reported by the manufacturers were compared to those reported by the external quality control agent of GDF, revealing analytical challenges in case of kanamycin assay and rifampicin dissolution testing.
These observations may encourage other organizations to systematically record and analyze such data in future, which can expand and improve the basis for the evaluation of QA/QC data within and between organizations.
Have a nice reading!,
PS Interested in our new short course on Pharmaceutical Policies in Health Systems? Please check https://edu.itg.be/courses/pharmaceutical-policies-in-health-systems
PS Are you on Twitter? Follow us for more updates at @RRavinetto and @QUAMED1